FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
clinicaladvisor.com6h
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
AFP3d
Vertex Announces US FDA Approval of ALYFTREKâ„¢, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease ...
Monthly Prescribing Reference6d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
Credit: Vertex. According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment. An additional 94 non-F508del CFTR mutations and a boxed ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Zacks Research Has Positive Estimate for VRTX Q3 Earnings
Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...
Yahoo Finance5d
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex is best known for its therapies for the rare lung disease cystic fibrosis (CF). Its steady work over the year delivered a large market share in CF therapies. Coming off of Novo Nordisk's ...
Businessworld4d
gloucestershire county cricket club vs sussex county cricket club match scorecard
The top 10 pharmaceutical stocks are released! Hengrui Medicine aims to hit a market value of 370 billion yuan ASH | BTK inhibitor development trends: Eli Lilly, BeiGene, and AZ announce clinical resu ...
pharmaphorum3d
Celebrations as NHS England agrees deal for Vertex’ cystic fibrosis triple
NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...